A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008597/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin
regimen of multiple daily injections (MDI) or continuous subcutaneous insulin infusion
(CSII). Randomisation to 3 treatments arms (equal assignment) following a screening period,
an optimisation period and a run-in period. 52 week double-blind treatment period, and 3 week
follow-up period.
提供机构：
Vivli
创建时间：
2022-11-21
